Volume 53, Issue 6 pp. 974-979

Pulse steroids as induction therapy for children with ulcerative colitis

Takahiro Kudo

Corresponding Author

Takahiro Kudo

Department of Pediatrics, Juntendo University School of Medicine

Takahiro Kudo, MD, Department of Pediatrics, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Email: [email protected]Search for more papers by this author
Satoru Nagata

Satoru Nagata

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Kiyotaka Ohtani

Kiyotaka Ohtani

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Tohru Fujii

Tohru Fujii

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Mariko Wada

Mariko Wada

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Hidenori Haruna

Hidenori Haruna

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Hiromichi Shoji

Hiromichi Shoji

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Yoshikazu Ohtsuka

Yoshikazu Ohtsuka

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Toshiaki Shimizu

Toshiaki Shimizu

Department of Pediatrics, Juntendo University School of Medicine

Search for more papers by this author
Yuichiro Yamashiro

Yuichiro Yamashiro

Probiotics Research Laboratory, Juntendo University Graduate School of Medicine, Tokyo, Japan

Search for more papers by this author
First published: 27 May 2011
Citations: 7

Abstract

Background: Corticosteroids therapy, classically the first-line treatment for ulcerative colitis (UC), often causes serious side-effects. Theoretically, pulse steroid therapy where high doses are given for a shorter period may have maximal beneficial effects and minimal side-effects as induction therapy for UC. We have therefore retrospectively compared induction therapy using pulse steroids with conventional steroid treatment for children and adolescents with moderate-to-severe UC.

Methods: We utilized conventional steroid treatment (prednisolone 1–1.5 mg/kg/day) as an induction treatment in 17 UC patients between 1985 and 2006. Alternatively we used a 3-day megadose pulse steroid therapy (methylprednisolone intravenously 20–30 mg/kg/day, max. 1000mg/day) in 20 UC patients from 1993 to 2006.

Results: Pulse steroid therapy successfully induced rapid remission in UC patients with moderate-to-severe disease compared with conventional treatment (13.2 days vs 25.1 days; P < 0.05). The amelioration of Pediatric Ulcerative Colitis Activity Index score between before and 1 week after pulse steroid therapy was significantly more than that of conventional treatment (P < 0.01). No serious adverse effects were observed in the patients treated with pulse steroid therapy. However, the rate of the relapse episodes during the next 12 months after pulse steroid therapy was not significantly different from that after conventional treatment.

Conclusion: These findings suggest that pulse steroid therapy is an option to be considered in children with moderate-to-severe UC.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.